Skip to main content
. 2020 Jun 24;12(6):585. doi: 10.3390/pharmaceutics12060585

Figure 4.

Figure 4

Analysis of binding between rhodamine B-labeled liposomes and breast cancer cells using flow cytometry. BT-474 and MDA-MB-231 cells were treated with control, ScrErbB2Lipo, and ErbB2Lipo. (A) Plots of flow cytometry results and (B) quantitative analysis of Figure 4A.